Popular on eTradeWire
- Pyrrhic Press Publishing Establishes Thought Leadership and Expands Global Influence Through PULSE - 160
- The Common Thread That Unites Us All - 150
- Women's Flag Football Coming to Cal Lutheran - 128
- Volusia Memorial Hosts First Annual Candlelight Service of Remembrance - 115
- Shoe Elegance Relaunches as an Online Boutique, Reviving Timeless Style and Sophistication - 111
- AI In Career Development: A Comprehensive Guide - 108
- Rising XR Startup Omnia shows off Virtual Showroom at Tesla Event - 105
- Seasonal holiday décor on display at Guadalupe Resale Shop - 104
- UDC Faculty Named Fellows by Academy of International Business - 102
- Choosing The Best Bed Bug Extermination Services ✨ - 102
Similar on eTradeWire
- Routine Dental Cleanings in Bethlehem Keep Smiles Healthy and Bright
- The Process of Braces Simplified at Exeter Smiles in Allentown
- New Hope Physiotherapy Inc Introduces Acupuncture Therapy in Brampton to Enhance Wellness & Recovery
- Icon Dental Updates Website to Highlight Med Spa Services in Downtown Denver
- 418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
- Cures Within Reach and Open Philanthropy Expand Partnership to Address Factors that Lead to High Disease Burden in Low / Lower-Middle Income Countries
- Saving Lives in Schools: The Urgency of CERP Legislation
- B2B Success for Regenerative Medicine Providers
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- BHRT Training Academy Announces inaugural BHRT 'Symposium at Sea 2025' for Healthcare Providers
The ROS1ders Announce Recipient of Eunice and Milton Ring Grant for ROS1 Cancer Research
eTradeWire News/10771050
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - eTradeWire -- The ROS1ders announced the recipient of the 2024 Eunice and Milton Ring Grant for ROS1 Cancer Research. Funding for this grant is provided by Eunice and Milton Ring, whose daughter Karen Ring Weiss is a member of the ROS1+ cancer community.
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on eTradeWire News
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on eTradeWire News
About ROS1+ Cancer
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on eTradeWire News
- Hotel Huddle Simplifies Group and Corporate Hotel Bookings with Intuitive New Platform
- EcoOptiView Smart Window Coating Solutions Inc. Introduces Innovative Energy-Efficient Technology
- Transforming Composite Coating Processes for Australia's Critical Industries
- Estate Planning Webinar for Families
- The IV Hall Group LLC Launches Transformational Campaign
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on eTradeWire News
- Pyrrhic Press Publishing Recognized as a New Jersey Sustainable Business by the NJSBDC
- OpenStax celebrates 25 years of transforming education
- Breaking: Federal Court Says City Of Los Angeles Must Answer Homelessness Lawsuit
- Comprehensive Guide to Sales CRM Software and Lead Tracking Software
- Green Air Environmental, Llc Awarded A Gsa Multiple Award Schedule Contract # 47QSMS24D00C4
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but currently for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders
0 Comments
Latest on eTradeWire News
- AXELERA Technologies Captivates at I/ITSEC - with Revolutionary 3D-4X Joystick and Drone Solutions
- New Hope Physiotherapy Inc Introduces Acupuncture Therapy in Brampton to Enhance Wellness & Recovery
- XPRIZE awards to inspire change
- Two venues with Mondo tracks named "Facility of the Year" by ASBA
- Niche Ranks Moravian Academy in the Top 3 Best Private K-12 Schools in Pennsylvania
- AXELERA Technologies Brings Warmth and Hope to Students in Kissimmee
- Data SIM Card for Saudi Arabia Stay Connected with eSIMs
- Icon Dental Updates Website to Highlight Med Spa Services in Downtown Denver
- Comp U Floor ERP vs. FloorZap: Discover the Best Flooring Business Software
- Vision Share Launches New Website to Better Serve Customers and Stakeholders
- Las Vegas Comedian Guy Fessenden Takes the Stage as Resident Host at Delirious Comedy Club
- Prati Italia offering Sunday Santa-themed Brunch events
- Women in Business to host Sweethearts & Scholarships Feb. 5
- Work With A Local Property Mgmt. Co. & Save Time & Money
- Delirious Comedy Club Welcomes Don Barnhart Back To Las Vegas Residency
- Merry Madness Downtown Downers Grove
- IP4Pros Launches Exclusive AI-Powered Patent Drafting Tool for Graduating Law Students
- PADT Deepens Commitment to Arizona Manufacturing as State's First NOCTI Certified Additive Manufacturing Site
- Calling all seafood lovers, boat enthusiasts, and car aficionados!
- Bradford College Officially Opens STEM Building After £6.9m Refurb